On Feb. 7, CLSA held its annual Back to Session Reception to welcome legislators back to Sacramento for the commencement of another legislative year, as well as to honor those legislators identified by CLSA membership as Life Sciences Champions. Dozens of legislators and at least two hundred other attendees packed the Ella Dining Room and Bar to see the presentation and mingle with those representing the life sciences industry, among others.
Following the Feb. 16 deadline for submitting new legislation to be considered for enactment this year, CLSA expects to see more than a dozen bills related to opioids when the dust settles. The ultimate number of bills dealing with the subject will not be apparent immediately, as many are introduced in a generic format, which is called a “spot bill,” and later amended with more specific language.
Legislators Honored with Award for Commitment to Strengthening California Life Sciences Sector at CLSA’s Back to Session Reception in Sacramento
On Jan. 18, Assemblymembers Kevin McCarty (D-Sacramento) and Phil Ting (D-San Francisco) introduced Assembly Constitutional Amendment 22, which would raise corporate taxes on California companies with annual net revenues higher than $1 million. The state tax increase on these corporations is intended to be equivalent to half of the federal tax cut recently signed into law.
While several opioid-related bills were introduced last year in California’s legislature, many in Sacramento anticipate a double-digit number of opioid-related bills to be introduced this year.
CLSA today issued the following statement applauding Governor Jerry Brown’s 2018 – 2019 California budget proposal that calls for $30 million to be invested in precision medicine research and the establishment of the California Institute to Advance Precision Health and Medicine (CIAPHM).
On Dec. 8, the Pharmaceutical Research and Manufacturers of America (PhRMA) filed suit in the United States District Court for the Eastern District of California, seeking to have Senate Bill (SB) 17’s manufacturer reporting requirements declared unconstitutional and void.
Shortly before Thanksgiving, California’s Office of Statewide Health Planning and Development (OSHPD) released its implementation plan for Senate Bill 17 (Hernandez). The bill was signed into law in October, and its advance notice provisions take effect on Jan. 1, 2018.
Despite the best efforts of CLSA and its partner trade associations, both Senate Bill 17 (Hernandez) and Assembly Bill 265 (Wood) reached the Governor’s desk and were signed into law.
In addition to Senate Bill 790 (McGuire), which was discussed in last month’s bulletin, several bills on which CLSA was active failed to become law this year. Unlike SB 790, these were bills CLSA had supported to varying degrees during the legislative process.